Fig. 2From: Patients harboring uncommon EGFR exon 19 deletion-insertion mutations respond well to first-generation EGFR inhibitors and osimeritinib upon acquisition of T790MPie charts illustrating the distribution of EGFR 19delins variants among 41 patientsBack to article page